USA: Topical tofacitinib 2% is effective for the treatment of refractory vitiligo, suggests a recent study published in the British Journal of Dermatology.
Vitiligo is a disease that causes the loss of skin color in blotches. It affects about 0.5% to 1% of the population and is associated with low self-esteem and social stigma. The medical approach to vitiligo patients is a complex process. Topical medications (corticosteroids and calcineurin inhibitors) and phototherapy are the mainstays of treatment. There are also other treatment options such as skin surgery and laser, but none of them has been able to provide consistent and satisfactory results in all patients.